José M. Fernández‐Fernández

This study shows that hypoglycosylation lowers the mechanical activation threshold of Piezo1, enhancing mechanotransduction in cortical neurons and linking glycosylation defects to neurological symptoms in PMM2-CDG.

The paper identifies Otenabant, a CB1 antagonist, as a potent and selective PIEZO1 inhibitor through high-throughput screening and validates its effects across multiple assays.